Implementation of a Depression Screening Intervention at a Transgender Health Clinic in Thailand

Thai Red Cross AIDS Research Centre317 enrolled

Overview

The study aims to develop and implement a depression screening intervention into routine HIV and sexual health service provision at a transgender health clinic in Thailand, and to explore the facilitators, barriers, feasibility and acceptability of the screening implementation.

The study will follow a mixed-methods approach that will incorporate quantitative and qualitative components. Aim 1 will involve the development and implementation of depression screening intervention at Tangerine Clinic. Aim 2 will involve semi-structured interviews with a purposive subset of participants who received the intervention and healthcare providers to explore the multilevel facilitators, barriers, feasibility and acceptability of the screening implementation. Aim 3 will evaluate the proportion of participants who are offered, accept, and receive the peer-led depression screening intervention, and the proportion who screen positive.

Study Type

INTERVENTIONAL

Allocation

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

317

Conditions

Depressive Symptoms

Interventions

Depression Screening InterventionBEHAVIORAL

All participants will be screened for depression using PHQ-2 and PHQ-9. Those screened positive for PHQ-2 but decline further screening with PHQ-9 will be assisted for further assessment or care. Those with mild to severe symptoms (score of 7 or higher on PHQ-9) will be assisted for further assessment or care with a psychiatrist.

Eligibility

Sex: MALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Thai nationality 2. Transgender women ≥18 years 3. Attending the Tangerine Clinic for routine care visits during the intervention period. 4. Can be a new or returning clients. Exclusion Criteria: 1\. Transgender women currently receiving care for a mental health diagnosis will be excluded from participating in this study. Inclusion Criteria for healthcare providers: 1. Currently working at the Tangerine Clinic 2. Can be medical doctors, nurses, peer counselors and other members of the clinic management team involved in the routine delivery of HIV and health services to Transgender women. Exclusion criteria for healthcare providers 1\. Not willing to participate in this study

Locations (1)

Institute of HIV Research and Innovation

Pathum Wan, Bangkok, Thailand

Outcomes

Primary Outcomes

Intervention Acceptability: Number of participants who accepted intervention

Acceptability will be measured by the number of clients who were offered and accepted the intervention.

Time frame: Day 1

Intervention Acceptability: Participants' perspective of the intervention through in-depth interviews

Acceptability will be assessed qualitatively through post-intervention in-depth interviews.

Time frame: Day 1

Intervention Acceptability: Participants' perspective of the intervention through focus group discussion

Acceptability will be assessed qualitatively through post-intervention focus group discussion.

Time frame: Day 1

Intervention Feasibility: Number of intervention completed

Feasibility will be measured by number of intervention completed. Point estimates of \>50% of participants completed is considered as the minimum criteria for feasibility.

Time frame: Day 1

Intervention Feasibility: Participants' perspective of the intervention through in-depth interviews

Feasibility will be assessed qualitatively through post-intervention in-depth interviews.

Time frame: Day 1

Intervention Feasibility: Participants' perspective of the intervention through focus group discussion.

Feasibility will be assessed qualitatively through post-intervention focus group discussion.

Time frame: Day 1

Number of participants screening positive for depression

Screening positive is defined as scoring 7 or greater on PHQ-9. The total possible score for PHQ-9 is 27, with 0-6 being minimum and indicating no depressive symptoms, 7-12 mild depression, 13-18 moderate depression, and 19-27 severe depression.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.